Φορτώνει......
Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
BACKGROUND: Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC). Everolimus acts synergistically with eribulin in TNBC cell lines and xenograft models. This phase I trial was designed to test the safety and tolerability of combinin...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Breast Cancer Res |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6839083/ https://ncbi.nlm.nih.gov/pubmed/31703728 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1202-4 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|